FDA Approves Merck's KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA® (pembrolizumab)
默克(US:MRK) Businesswire·2025-09-19 21:31药品批准 - 美国FDA批准KEYTRUDA QLEX™（帕博利珠单抗与贝拉透明质酸酶阿尔法-pmph复方制剂）用于皮下注射[1] - 该药品适用于成人绝大多数实体瘤适应症[1] - 贝拉透明质酸酶阿尔法由Alteogen Inc公司开发并生产[1]